Atypical teratoid rhabdoid tumor: current therapy and future directions

Kevin F. Ginn and Amar Gajjar*
Division of Neuro-Oncology, St. Jude Children’s Research Hospital, Memphis, TN, USA

INTRODUCTION
Primary central nervous system (CNS) atypical teratoid rhabdoid tumors (ATRTs) were identified as a separate entity relatively recently, as recognized by their addition to the World Health Organization (WHO) classification of tumors in 1993 (Biernat, 2000; Radner et al., 2002). The first reported cases appeared as multiple case reports in the late 1980’s and early 1990’s that described patients, for the first time, with isolated CNS ATRTs (Bonnin et al., 1984; Biggs et al., 1987; Ho et al., 1990; Chou and Anderson, 1991; Agranovich et al., 1992; Satoh et al., 1993). Previously reported cases of CNS rhabdoid tumors were often associated with malignant rhabdoid tumors (MRT) of the kidney, which had been identified a decade earlier upon central review of Wilms’ tumors treated in a collaborative group (Beckwith and Palmer, 1978). This group noted that certain patients had tumors with different pathologic features and that these features were associated with significantly worse outcomes. Similarly, ATRTs were often categorized with primitive neuroectodermal tumors (PNETs), along with medulloblastoma, due to histologic similarities, but they are now separated from other embryonal tumors by the presence of rhabdoid cells and specific immunohistochemistry (Biggs et al., 1987; Lefkowitz et al., 1987; Ho et al., 2000; Bikowska et al., 2011). Like rhabdoid tumors of the kidney, CNS ATRTs are also associated with significantly worse overall survival than other embryonal tumors.

Atypical teratoid rhabdoid tumors (ATRTs) are rare central nervous system tumors that comprise approximately 1–2% of all pediatric brain tumors; however, in patients less than 3 years of age this tumor accounts for up to 20% of cases. ATRT is characterized by loss of the long arm of chromosome 22 which results in loss of the hSNF5/INI-1 gene. INI1, a member of the SWI/SNF chromatin remodeling complex, is important in maintenance of the mitotic spindle and cell cycle control. Overall survival in ATRT is poor with median survival around 17 months. Radiation is an effective component of therapy but is avoided in patients younger than 3 years of age due to long term neurocognitive sequelae. Most long term survivors undergo radiation therapy as a part of their upfront or salvage therapy, and there is a suggestion that sequencing the radiation earlier in therapy may improve outcome. There is no standard curative chemotherapeutic regimen, but anecdotal reports advocate the use of intensive therapy with alkylating agents, high-dose methotrexate, or therapy that includes high-dose chemotherapy with stem cell rescue. Due to the rarity of this tumor and the lack of randomized controlled trials it has been challenging to define optimal therapy and advance treatment. Recent laboratory investigations have identified aberrant function and/or regulation of cyclin D1, aurora kinase, and insulin-like growth factor pathways in ATRT. There has been significant interest in identifying and testing therapeutic agents that target these pathways.

Keywords: ATRT, pediatric brain tumors, cyclin D1, aurora kinase, insulin-like growth factor, tyrosine kinase inhibitors

A recent review of the Surveillance, Epidemiology, and End Results (SEER) database from 1973 to 2008 estimated overall survival for ATRT patients at 10 months, and notably the year of diagnosis had no effect on survival, showing that little progress has been made since ATRTs were first identified (Buscariollo et al., 2011). Another review from the German HIT database from 1988 to 2004 showed 77% of patients with ATRT (43/56) died of disease [3-year event-free survival (EFS), 13 ± 5%; overall survival (OS), 22 ± 6%; von Hoff et al., 2011]. Investigators from The Hospital for Sick Children compiled data from four patients with ATRT at their institution with a retrospective review of 143 cases reported in the literature from 1995 through 2007 and found a median overall survival of 17.3 months (Athale et al., 2009). Overall, patients usually succumb to their disease between 6 months and 1 year from diagnosis. Survival is especially poor for patients with metastatic disease, which one registry found was present in around 20% of patients at diagnosis (Hilden et al., 2004).

ATRT accounts for 1–2% of CNS tumors in children of all ages, but 10–20% of tumors in patients less than 3 years old (Hilden et al., 2004; Tekautz et al., 2003; Biegel, 2006), who also tend to present with infratentorial tumors (70%; Rorke et al., 1996). The higher frequency of ATRT in patients less than 3 years old complicates therapy due to avoidance of radiation therapy (RT) in this age group, and these patients have shorter survival than older patients with the same tumor. Delayed radiation can affect
prognosis. Multiple chemotherapy approaches to defer radiation have been attempted, yet overall survival remains dismal.

In 1995, Rorke et al. (1995) published one of the earliest and largest case series of 32 infants with CNS ATRT. They found a 1.9:1 male-to-female ratio, a median age at diagnosis of 17 months, and an association with chromosome 22 abnormalities. In subsequent years, investigation into associated chromosome 22 abnormalities led to the identification of hSNF5/INI1 gene mutations that are now the defining feature of this entity and the main target of current research to identify new therapeutic approaches (Versteeg et al., 1998).

This aggressive tumor remains a significant challenge in pediatric neuro-oncology, and new therapeutic approaches are desperately needed. This review will summarize the published therapies to date and focus on recent basic science and translational studies as new potential targets are being identified in the laboratory and there is a need to push for advances in therapy that may lead to increased survival for patients with this devastating tumor.

**CHEMOTHERAPY**

Given the rarity of ATRTs and the variety of treatment regimens used to date, no standard therapeutic approach has been established. Published case series often include patients treated with multiple therapeutic approaches, making standardization of therapy difficult. Table 1 summarizes some of the larger clinical trials that included ATRT patients or that were designed specifically for ATRT. Early complexity determining the best therapeutic approach was evident in the reported proceedings of the tumor board of The Children’s Hospital of Philadelphia (CHOP) in 1991 (Perilongo et al., 1991). The group described a 5-year-old patient with a CNS primary rhabdoid tumor and detailed their consideration of therapeutic approaches including review of children with rhabdoid tumors of the kidney. Ultimately, they opted to treat with 3600 cGy craniospinal radiation with an unspecified boost dose to the primary site along with chemotherapy that was currently in use on the infant brain tumor therapeutic trials, including cisplatin, cyclophosphamide, vincristine, and etoposide.

In response to the report from CHOP, Weinblatt and Kochen (1992) from Cornell submitted a letter describing a patient they treated in 1985 with a primary CNS rhabdoid tumor with gross total resection (GTR), 4140 cGy focal radiation, and intensive chemotherapy as per the Intergroup Rhabdomyosarcoma III (IRS-III) therapy, including weekly vincristine during radiation, actinomycin-D, doxorubicin, and triple intrathecal chemotherapy with hydrocortisone, methotrexate, and cytosine arabinoside. An additional three cases successfully treated with IRS-III were then reported in 1995 by Ohio State University (Olson et al., 1995). This approach was justified because ATRT was thought to be similar to parameningeal rhabdomyosarcomas, requiring more aggressive therapy, and regimen 36 was chosen because it was intensive chemotherapy that was easily adaptable to radiation and triple intrathecal chemotherapy. This group also summarized the 18 cases of primary CNS MRTs previously reported in the literature to date, showing the varied approaches to therapy, and the need for a more standardized approach.

Dana-Farber Cancer Institute (DFCI) decided to return to the original early reports of success with IRS-III-based regimens to treat two new ATRT patients and two with recurrent disease between December 1999 and April 2002 due to unpublished reports of failures with modifications from the original therapy (Zimmerman et al., 2005). DFCI modifications included focal stereotactic RT without a craniospinal dose for patients less than 3 years old, substitution of dacarbazine with temozolomide, and addition of dextrazoxane for cardioprotection in higher cumulative doses of doxorubicin. All four patients were alive at the time of reporting at a median 44.5 months after diagnosis and a median 26.5 months after recurrence. A later update from the group at DFCI stated that three of the four were alive at a median 6.5 years after completion of therapy. DFCI then proceeded with a phase II study between February 2004 and September 2006 with a modified IRS-III protocol and treated 20 patients with ATRT (Chi et al., 2009). Eight of the 20 patients had relapses by the time of publication, giving a 1-year progression-free survival (PFS) rate of 70 ± 10% and OS of 75 ± 10% and 2-year PFS of 53 ± 13% and OS 70% ± 10%. Univariate analysis showed that PFS and OS were significantly influenced by the extent of resection. OS was also affected by tumor location, and patients with posterior fossa tumors had better survival. The reported PFS and OS were significantly better than those seen in other clinical trials but, due to small numbers, it was impossible to make comparisons to determine why there was such an improvement. This report did, however, point to improved survival with intensified chemotherapy that included intrathecal administration along with focal radiation for those patients younger than 3 years old. It would also have been useful with larger numbers to separate the overall survival data based upon age, as others have shown that survival is improved for older patients.

Modified IRS-III therapies include intrathecal chemotherapy as well as multiagent chemotherapy and focal radiation in patients who have non-metastatic disease. Intrathecal chemotherapy may have potential benefit as an additional means to avoid radiation or to intensify therapy in patients who are not candidates for craniospinal radiation. A meta-analysis by Athale et al. (2009) showed that even without GTR, patients who received multiagent chemotherapy fared better, but this effect was most prominent in those less than 3 years old who did not get radiation. Without radiation, intrathecal chemotherapy also made a significant difference in overall survival (OS 10.5 months versus 6.5 months, p = 0.011).

An additional approach to early therapy of ATRT was explored as these patients were included in national infant brain tumor clinical trials. The North American Children's Cancer Group from April 1993 through June 1997 enrolled 299 children less than 3 years old with multiple tumor types on protocol CCG9921 (Geyer et al., 2005). This regimen included two induction courses with ifosfamide or cyclophosphamide along with vincristine, cisplatin, and etoposide. Induction was followed by maintenance with vincristine, etoposide, carboplatin, and cyclophosphamide. The study included 28 rhabdoid tumors (9.4% of patients enrolled), and 24 of those had treatment failures. The 1-year and 5-year EFS rates were 32 ± 9% and 14 ± 7%, respectively, and the 5-year OS was 29 ± 9%. Interpretation of factors associated with prognosis was difficult due to the small numbers in this group. During the same period, the Pediatric Oncology Group was investigating the use of standard versus dose-intensified chemotherapy...
to delay radiation in young children on POG 9233/34 (Baby POG 2). The study enrolled 36 patients with ATRT. Chemotherapy included cyclophosphamide, vincristine, cisplatin, and etoposide. Patients on the dose-intensified arm had better responses, but all patients with rhabdoid tumors ultimately died, with a median survival of 6.7 months (personal communication, Douglas Strother).

Researchers from St. Jude Children’s Research Hospital in 2005 reported a retrospective review of 31 patients with ATRT treated between 1984 and 2003 (Tekautz et al., 2005). As expected, the patients were treated with multiple different approaches over the 20-year period, but overall they determined that outcomes were better for patients who were older than 3 years at diagnosis and those who had received craniospinal radiation and high-dose alkylator-based chemotherapy up front with a 2-year OS of 89 ±11%. Five of the nine patients older than 3 years were alive without recurrence at the time of publication at a median of 2.2 years, and it is important to note that seven of those patients had craniospinal radiation. In contrast, only four of 22 patients less than three were without relapse. One of the four died of a surgical complication; of the remaining three, two received RT.

The Canadian Pediatric Brain Tumor Consortium recently published a retrospective review of patients with ATRT treated from 1995 through 2007 (Lafay-Cousin et al., 2012). They identified 50 patients, and although there were multiple different therapies during the period, they were able to make several conclusions from their analysis. As expected, the prognosis was much worse for patients younger than 12 months. Patients with GTR had better responses, compared to other chemotherapy approaches although numbers are small in all series and it is difficult to separate the role the modifications of the IRS-III regimen. As stated earlier, intrathecal

| Study time period | n of patients | Age | Type of study | Chemotherapy | Radiation | Survival |
|-------------------|---------------|-----|---------------|--------------|-----------|----------|
| Tekautz et al. (2005) | 31 | 22 patients <3 years (median 1 year), 9 patients ≥3 years (median 3.9 years) | Retrospective review | Multiple regimens | <3 years 2 local, 1 CSI + boost | <3 years (estimates) |
| July 1984–June 2003 | | | | | 2-year EFS 11 ± 6% | 2-year OS 17 ± 8% |
| Geyer et al. (2005) | 28 | 12 patients aged 0–11 months, 6 patients aged 12–17 months, 10 patients aged 18–36 months | Phase II/III | Induction A (n = 16), VCR/CDDP/CTX/VP + Maintenance | 2 patients prior to progression (1 focal, 1 CSI) | 1-year EFS 32 ± 9% |
| CCG9921 | | | | | 2-year EFS 14 ± 7% | 5-year EFS 14 ± 7% |
| April 1993–June 1997 | | | | | 5-year OS 29 ± 9% |
| Douglas Strother [personal communication 2011] POG9233/34 1992–1998 | 33 | All patients <3 years | Phase III | CTX/VCR/CDDP/VP Standard versus dose-intensified | None | 5 year OS 0% |
| | | | | | Median survival 6.7 months. |
| Lafay-Cousin et al. (2012) | 50 | Median age 16.7 months, 17 patients aged <12 months, 21 patients aged 12–36 months, 12 patients >36 months | Retrospective review | Multiple regimens 22 conventional | 21 patients at some point during therapy | 2-year OS 36.4 ± 7.7% |
| 1995–2007 | | | | | 2-year OS 36.4 ± 7.7% |
| Chi et al. (2009) | 20 | Median 26 months (2.4 month–9.5 years) | Phase II | Modified IRS-II 54 Gy focal (n = 11), 36 Gy CSI + boost (n = 4) | 2-year PFS 33 ± 13% |
| 2004–2006 | | | | | 2-year OS 70 ± 10% |

CDDP, cisplatin; CSI, craniospinal radiation; CTX, cyclophosphamide; EFS, event free survival; IFOS, ifosfamide; IRS, Intergroup rhabdomyosarcoma study; OS, overall survival; PFS, progress free survival; VCR, vincristine; VP, etoposide.
chemotherapy has been associated with improved survival in those patients that did not receive radiation. In the IRS-III based regimen, the combination of Intrathecal chemotherapy with focal radiation in those patients less than 3 years of age may be an effective strategy for disease control, but Intrathecal chemotherapy in those patients older than 3 years may not be needed since craniospinal radiation is an acceptable option. It is clear that intensive systemic chemotherapy alone as a method to avoid radiation is not effective in ATRT and radiation must be considered much earlier in therapy than previously thought appropriate, but with continued respect for long term effects.

Since 2008, the Children's Oncology Group (COG) has been enrolling patients with ATRT on a clinical trial that incorporates induction chemotherapy with high-dose methotrexate, focal radiation in patients as young as 6 months for infratentorial tumors and 12 months for supratentorial tumors, and three cycles of consolidation with thiotepa and carboplatin with autologous stem cell support. This therapeutic protocol thus incorporates focal radiation in younger patients than on previous COG protocols. High-dose methotrexate was included based on data from the Head Start (HS) protocols discussed later and the three cycles of consolidation are based on CCG 99703 for which data has yet to be published. The study was closed for 1 year due to the toxic death of one patient but has been reopened with amendments concerning pulmonary toxicity monitoring and increased time between consolidation courses. Enrollment is ongoing, and the accrual rate is as expected for this rare tumor.

RADIATION

Previous studies that aimed to avoid or delay radiation in ATRT patients less than 3 years old were associated with a very poor prognosis, and some clinical trials now incorporate focal radiation in much younger patients than previously thought appropriate. Radiation has been associated with improved survival in ATRT, especially in patients who have craniospinal radiation with a focal boost to the tumor bed. There are two published series that were intended to address the issue of radiation in patients with ATRT, and both support radiation as soon after surgery as possible. Other case series in the literature are not included here, but most show outcomes are better in patients who received radiation as noted previously.

St. Jude researchers reviewed 31 ATRT patients treated from 1987 through 2007, which also included some patients previously reported by Tekautz et al. (2005), and aimed to evaluate patterns of failure and local control with radiation (Pai Panandiker et al., 2011). Again, patients had varying chemotherapy regimens and extent of resection, but all were treated with focal radiation alone or with the addition of craniospinal irradiation (CSI). At a median follow up of 48 months, the PFS was 32.2 ± 10%, and OS was 53.5 ± 10%. Using a Cox regression model, they showed that patients with a GTR and stable disease before RT were less likely to experience an adverse event, while conversely patients with delayed RT were more likely to experience an event. Delayed RT was defined as ≥1 month from surgery. Overall survival was affected only by disease progression before RT in their analysis. Metastatic disease at presentation did not significantly affect PFS or OS. Those with less than GTR had a local failure rate of 53.3 ± 14% at 4 years, and those with GTR had a local failure rate of 17.9 ± 10%. Of those who had immediate postoperative CSI, 29% (2/7) experienced local failure compared with 58% (7/12) of those who had delayed postoperative CSI. The six patients younger than 3 years who were alive at last follow up before publication all had focal RT.

Seventeen patients with ATRT were treated at Taipei Veterans General Hospital in Taiwan between January 1990 and December 2003 (Chen et al., 2006). Fifteen of 17 patients had the standard study regimen of CSI ranging from 2550 to 3600 cGy for prophylaxis or 3600 cGy plus a focal boost up to 4400 cGy for spinal seeding. The total primary dose ranged from 4860 to 5600 cGy. Two of 17 patients had whole brain radiation with a focal boost. Patients received varying approaches to chemotherapy before, during, or after radiation, with the most common chemotherapy including vinblastine, ifosfamide, and cisplatin. Nine of the 17 received intrathecal chemotherapy with either methotrexate or nimustine. The median OS was 17 months and 14 (82%) had relapses with median time from relapse to death of 6 months. The group found no difference in OS or failure-free survival between doses more or less than 5000 cGy. Multivariate analysis showed a significant relationship between the interval between surgery and RT (p = 0.031) and the time to radiation completion (p = 0.047). When evaluating the six surviving patients at the time of publication, three of whom had no evidence of disease, and one of those who had never received any chemotherapy, they noted that these patients tended to be older, had a GTR, and completed CSI with a focal boost.

HIGH-DOSE CHEMOTHERAPY

Table 2 summarizes patients reported in the literature who have had HDC as a significant element of their therapy for ATRT. For each study listed in the table, only the patients who proceeded to the HDC phase of therapy are shown. HDC with autologous stem cell rescue has been used not only as salvage therapy for patients with relapsed disease, but also as a method of intensifying initial chemotherapy to delay irradiation in young patients. St. Jude researchers retrospectively reviewed 27 cases of recurrent malignant brain tumors treated with HDC with autologous stem cell rescue between March 1989 and May 2004. Of the 27 patients treated with multiple chemotherapy regimens, only two had a diagnosis of ATRT. The estimated 5-year PFS for all embryonal tumors in patients less than 3 years old at the time of diagnosis was 66.7 ± 22.2% versus 7.1 ± 4.9% for those 3 years or older. This difference was likely because the patients younger than three were able to be salvaged with HDC and radiation, whereas those older than three had previously received radiation so it was not an option for salvage. One patient with ATRT who was 1 year old was treated with chemotherapy alone at diagnosis and had residual tumor with positive cerebrospinal cytology before HDC. Salvage therapy included high-dose cyclophosphamide and topotecan; disease persisted after HDC. Time to progression was 39 days, and the patient died of disease 70 days after salvage therapy. The other patient with ATRT, also 1 year old, received chemotherapy alone at diagnosis and had no evidence of disease at time of salvage therapy, which included focal RT and HDC with cyclophosphamide and topotecan. At the time of publication, he remained alive with no evidence...
| Published report | Type of study | Age (month) | Pre-HDCT treatment | Disease status prior to HDCT | RT | HDCT | Response to HDCT | Relapse data | Adjuvant therapy | Survival outcome |
|------------------|--------------|-------------|--------------------|-----------------------------|----|------|-----------------|-------------|-----------------|-----------------|
| Shih et al. (2008) | Recurrent/refractory | 12 | Chemotherapy | Nodule, CSF+ | None | CTX/TOPO | PD | None | None | 70 days from day +1, DOD 862+ days from day +1, alive, NED |
| Gardner et al. (2008) | De novo therapy, Head Start I protocol, Induction with CDDP, VP-16, CPM, and VCR | 45 | HS-I induction courses x3 (no VP during cycle 3) | NED | None | CARBO/THIO/VP | NED | Local | None | 10.5 month, DOD |
| | De novo therapy, Head Start II protocol, Induction as per, HS-I + HD-MTX | 44 | None | GTR, M3 | None | CARBO/THIO/VP | CR | LMD, right frontal lobe | None | 10.5 month, DOD |
| | | 52 | HS-II induction courses x5 (no MTX) | CR | None | CARBO/THIO/VP | CR | N/A | None | Alive, 67+ month, NED |
| | | 23 | HS-II induction courses x5 | CR | None | CARBO/THIO/VP | CR | N/A | None | Alive, 42+ month, NED |
| | | 5 | HS-II induction courses x5 (no CDDP during course 5 due to ototoxicity) | CR | CSI after HDCT before relapse | CARBO/THIO/VP | CR | Local, LMD, PF, SC | None | 11.5 month, DOD |
| | | 48 | HS-II induction courses x5 | CR | Involved field after relapse | CARBO/THIO/VP | SD | Local | None | 36 month, died of 2nd leukemia |
| | | 91 | ICE x4 | CR | Yes | VP/THIO/CTX | CR | NONE | None | Alive, 54+ month, NED |
| | | 44 | ICE x2 | PR | On therapy | On therapy | N/A | None | None | Alive, 105+ month, NED |

(Continued)
Table 2 | Continued

| Published report | Type of study | Age (month) | Pre-HDCT treatment | Disease status prior to HDCT | RT | HDCT | Response to HDCT | Relapse data | Adjuvant therapy | Survival outcome |
|------------------|--------------|-------------|--------------------|-----------------------------|----|------|------------------|-------------|----------------|-----------------|
| Finkelstein-Shechter et al. (2010) | Retrospective review of patients treated 2003–2008 | 43 | 5 patients had 3 cycles VP-16, CTX, CDDP, VCR; 1 pt treated with IRS-III | Not reported | None | 3 cycles of CARBO/THIO | Not reported | N/A | None | Alive, 64 month, NED |
| | | 11 | None | N/A | TAM | Alive, 51 month, NED |
| | | 31 | Focal | N/A | None | Alive, 52 month, NED |
| | | 40 | Focal during first 2 chemo cycles | Relapse 16 month | None | DOD |
| | | 39 | None | Relapse 8 month | TAM | DOD |
| | | 28 | None | N/A | Intraventricular TOPO, TAM-ATRA | None | Alive, 23 month, NED |
| Nicolaides et al. (2010) | De novo therapy May 1997–January 2007 (3 patients died of disease prior to HDCT) | 49 | MTX, CTX, VP, CDDP, VCR (HSII) | CR | Local | CARBO/VP/THIO | Not reported | N/A | None | Alive, 78 month, NED |
| | | 46 | T-IT, CDDP, VP, VCR, AD, IFOS, CTX | CR | None | CARBO/VP/ MELPH/CTX | Not reported | Disseminated at 2 month | None | DOD, 10 month |
| | | 15 | MTX, CTX, VP, CDDP VCR, IT-A RAC | CR | None | CARBO/THIO/VP | Not reported | Disseminated at 3 month | None | DOD, 10 month |
| | | 6 | MTX, CTX, VP, CDDP VCR (2/3 with MTX) | CR | None | THIO/TOPO/VP | Not reported | N/A | None | Alive, 96 month, NED |
| | | 9 | CDDP, VP, VCR, CTX | CR | None | CARBO/THIO | Not reported | Distant relapse | None | DOD, 13 month |
| | | 33 | CDDP, VP, VCR, CTX | CR | None | CARBO/THIO | Not reported | N/A | None | AW, 19 month |
| Published report | Type of study | Age (month) | Pre-HDCT treatment | Disease status prior to HDCT | RT | HDCT | Response to HDCT | Relapse data | Adjuvant therapy | Survival outcome |
|------------------|---------------|-------------|--------------------|-----------------------------|----|------|-----------------|-------------|----------------|-----------------|
| Park et al. (2012) | De novo therapy, phase III prospective trail tandem HDCT September 2005-March 2010 | 4 | Alternating CECV and CEIV x6 cycles | PR | None | CARBO/THIO/VP then CTXMELPH | Not reported | Progression at 13 month | None | DOD, 15 month |
|                  |               | 9 | Alternating CECV and CEIV x6 cycles | PD | CSI/boost (after HDCT) | CARBO/THIO/VP then CTXMELPH (after PD, surgery, then HDCT followed with RT) | Not reported | Progression at 8 month then surgery, HDC1/2, then RT | None | Alive, 16+ month, NED |
|                  |               | 11 | Alternating CECV and CEIV x6 cycles | CR | Local | CARBO/THIO/VP then CTXMELPH (after relapse) | Not reported | Relapse at 6 month then repeat surgery, RT, and HDCT1/2 | None | Alive, 50+ month, NED |
|                  |               | 12 | Alternating CECV and CEIV x6 cycles | CR | CSI/boost (after progression) | CARBO/THIO/VP then CTXMELPH | Not reported | Relapse at 21 month post HDCT then Sx, CECV/CEIV, RT | None | Alive, 70+ month, NED |
|                  |               | 15 | Alternating CECV and CEIV x4 cycles | PR | CSI/boost (after progression) | CARBO/THIO/VP then CTXMELPH (after progression) | Not reported | Progression at 4 month then Sx, RT, HDCT1/2, progression, CTx | None | AWD, 19+ month |
|                  |               | 28 | Alternating CECV and CEIV x6 cycles | PR | CSI/boost after HDCT | CARBO/THIO/VP then CTXMELPH | Not reported | N/A | None | Alive, 20+ month, NED |

AD, actinomycin D; ATRA, all-trans retinoic acid; AWD, alive with disease; CARBO, carboplatin; CDDP, cisplatin; CECAT, cyclophosphamide, etoposide, carboplatin, thiotepa; CECV, cisplatin, etoposide, cyclophosphamide, vincristine; CEIV, carboplatin, etoposide, ifosfamide, vincristine; CR, complete response; CSF, cerebrospinal fluid; CSI, craniospinal radiation; CTX, cyclophosphamide; DOD, died of disease; GTR, gross total resection; HDCT, high-dose chemotherapy; ICE, ifosfamide, carboplatin, etoposide; IFOS, ifosfamide; IT-ARAC, intrathecal cytosine arabinoside; LMD, leptomeningeal disease; MELPH, melphalan; MTX, methotrexate; NED, no evidence of disease; PD, progressive disease; PF, posterior fossa; RT, radiation therapy; SC, spinal cord; SD, stable disease; TAM, tamoxifen; THIO, thiotepa; T-IT, triple intrathecal chemotherapy; TOPO, topotecan; TVD, topotecan, vincristine, doxorubicin; VCR, vincristine; VP, etoposide.
of disease after more than 862 days (Shih et al., 2008). Although it is difficult to generalize this information, the results are as would be expected, in that patients with minimal to no detectable disease at the time of HDC are more likely to have prolonged survival.

Gardner et al. (2008) reported their experience treating patients with CNS ATRT enrolled on the HS I and II protocols. Thirteen patients underwent surgical resection followed by five cycles of induction chemotherapy and a single course of HDC with stem cell rescue. HS-II differed from HS-I with the addition of methotrexate to induction agents including cisplatin, etoposide, cytoxan, and vincristine. Consolidation chemotherapy included carboplatin, thiopeta, and etoposide. If the patient had no evidence of disease at the end of induction, regardless of second look surgery, then the patient proceeded to consolidation. If there was evidence of residual disease locally or with positive cerebrospinal cytology, consolidation was followed by RT. Four of 13 patients did not get all five induction courses, and one patient had no induction chemotherapy and proceeded straight to consolidation. One patient treated with HS-II who had only 1 cycle of induction died of Staphylococcus aureus meningitis. During induction there were eight episodes of bacterial sepsis among six HS-I patients, and all seven patients on HS-II had bacterial sepsis. Three of the 13 patients had fungal infections. Only two of the six HS-I patients and five of the seven HS-II patients went on to consolidation. RT was utilized in two HS-I and two HS-II patients. All six of the HS-I patients died of disease, but three of the seven HS-II patients were alive at the time of publication with no evidence of disease, and none had RT. There may have been a benefit to patients who were alive at the time of publication with no evidence of disease, and five of the seven HS-II patients went on to consolidation. RT all seven patients on HS-II had bacterial sepsis. Three of the 13 patients who had only 1 cycle of induction died of Staphylococcus aureus meningitis. During induction there were eight episodes of bacterial sepsis among six HS-I patients, and all seven patients on HS-II had bacterial sepsis. Three of the 13 patients had fungal infections. Only two of the six HS-I patients and five of the seven HS-II patients went on to consolidation. RT was utilized in two HS-I and two HS-II patients. All six of the HS-I patients died of disease, but three of the seven HS-II patients were alive at the time of publication with no evidence of disease, and none had RT. There may have been a benefit to patients who received methotrexate, as all patients on HS-I died of their disease, whereas the reported EFS for HS-II was 43 ± 19% at 3 years. They also further supported that near total or GTR led to better outcomes than subtotal or partial resection with a significant difference in OS at 57 ± 18 versus 0%. The estimated EFS and OS at 3 years was 23 ± 11%. Although this analysis may show a possible benefit to the use of methotrexate and further supports better outcomes with more complete resection, the 3-year estimated EFS is comparable to that achieved with other therapeutic approaches.

A group from Italy reported eight patients treated on a clinical trial that included radiotherapy; ifosfamide, carboplatin, and etoposide (ICE); and HDC (Fidani et al., 2009). They had originally included cyclophosphamide, etoposide, carboplatin, and thiopeta, but after three of four patients had progressive disease on this therapy, they decided to exclude these courses and replace them with additional ICE. Only one of eight patients had metastatic disease at diagnosis, and complete resection was achieved in three patients. They defined overall survival as the time from the date of diagnosis until the date of death with a reported OS probability at 5 years of 50%. The group admits that the patient numbers were too small to make any real determination of survival compared with historic controls. Of the five patients who were reported as still alive at the time of publication, one did not proceed to HDC, one had relapse before HDC, one had relapse after HDC but was alive with salvage therapy, one proceeded through planned therapy including HDC and has no evidence of disease, and one was currently on therapy at the time of publication.

Researchers at The Hospital for Sick Children in Toronto reviewed their experience with HDC in ATRT from 2003 through 2008 and found six evaluable patients (Finkelstein-Shechter et al., 2010). All six patients had three cycles of carboplatin and thiopeta conditioning, although there were some differences in other therapies received by each patient. They reported four of six patients alive with no evidence of disease at a median follow up of 52 months, and three of the four patients did not receive any radiation. A team from the University of California, San Francisco, reported their experience with HDC in nine patients treated at their institution between 1997 and 2007 (Nicolaides et al., 2010). Patients had varied postsurgical therapy and conditioning regimens. They reported two patients alive with no evidence of disease after 78 and 98 months and one alive with disease after 19 months. Most recently a group from Korea enrolled nine patients on a prospective phase I/II trial to investigate tandem transplants in ATRT with course one including carboplatin, thiopeta, and etoposide and course two with cyclophosphamide and melphalan (Park et al., 2012). During therapy, five of the nine had progressive disease, and one patient died of disease. The remaining four were salvaged and proceeded to tandem transplants. All patients on this trial were treated with the same conditioning regimen, which should make comparison easier, but of the five alive at the time of reporting, four had some deviation from therapy for salvage after progression. The protocol was written to allow for salvage therapies in the event of progressive disease while still allowing the patient to proceed to HDC. There was only one patient who proceeded through planned therapy including the post-transplant radiation without progressive disease. They reported a 3-year OS of 53.3 ± 17.3% and EFS of 0% and admitted that radiation may have been the most important component of therapy in the survivors.

No real conclusions can be made from published data regarding the role of high-dose chemotherapy in ATRT due to small patient numbers, multiple chemotherapy regimens, and additional salvage therapy that often includes radiation. The HS II protocol does point to increased survival with the addition of high-dose methotrexate to intensive chemotherapy, one course of high-dose chemotherapy and avoidance of radiation. This difference is likely due to additional systemic therapy targeted for better CNS penetration rather than the importance of continued inclusion of high-dose chemotherapy. Upfront intensive multimodal therapy for ATRT is needed, but the role of high-dose chemotherapy with autologous stem cell rescue remains unclear and its use should be balanced with overall toxicity of therapy.

INVESTIGATING NEW THERAPEUTIC TARGETS

The most often encountered genomic aberration in ATRT is monosomy 22 or a deletion or translocation of 22q11.2, which is best identified through fluorescence in situ hybridization (FISH; Biegel, 2006). Inactivating mutations of the SMARCB1 gene (hSNF5/INI-I) at 22q11.2 is thought to be a crucial step in tumorigenesis (Biegel, 2006), but mutations can be identified in only about 76% of CNS ATRT tumor samples (Biegel et al., 2002). INI1 is one member of the BRG-associated factor (BAF) or SWI/SNF complex, which are important in chromatin remodeling (Biegel, 2006; Venneti et al., 2011). In 1998, Versteeg et al. (1998) reported their work with 13 cell lines in which they identified the most frequent mutations in the hSNF5/INI1 gene. They compared their
findings with corresponding primary tumor samples to verify that the mutations did not occur as a result of in vitro growth. The identified biallelic alterations corresponded with the “two-hit” model of oncogenesis. More recently a group has shown through whole-exome sequencing of 32 samples of rhabdoid tumors, which included 20 CNS tumors, that the overall mutation rate is relatively low in primary samples (Lee et al., 2012). The primary rhabdoid tumor genome was seen as relatively simple, but when three recurrent tumor samples were tested and compared to primary samples the mutation rate was increased eightfold. Other investigators at the time this genetic link became apparent were looking into the role of SWI/SNF complexes in cell cycle control. It was shown that complexes of activated versus inactivated retinoblastoma protein (Rb) with histone deacetylase (HDAC) and SWI/SNF controlled cell cycle progression through the G1 and S phases through the E2F pathway (Zhang et al., 2000). Using malignant rhabdoid cells, it was shown that ectopic expression of hSNF5/INI1 blocks entry into S phase, but this effect can be reversed by cyclin D1 or cyclin E (Versteeghe et al., 2002).

Since 1998, when the hSNF5/INI1 gene was identified as playing a role in MRTs, work to understand the mechanism that drives ATRT has provided potential therapeutic targets. Using the MON cell line, a group from Albert Einstein College of Medicine reintroduced INI1 and then analyzed a cDNA microarray to determine expression changes that may result in new therapeutic targets (Morozov et al., 2007). They found 63 genes that were upregulated and 18 that were downregulated. The majority of the downregulated genes were important in mitosis, including topoisomerase II alpha (TOP2A), aurora A (STK6), polo-like kinase (PLK), kinesin family member 2C (KIF2C), centromere protein F (CENPF), and pitiutary-tumor transforming gene 1 (PTTG1). They found that interferon-stimulated genes were significantly increased early after the reintroduction of INI1. They then treated MON and STA-WT1 rhabdoid cell lines with interferon-alpha or -beta and found that, compared with controls, there were reduced cell numbers and increased flat cells 5–7 days after one round of replating. INI1 reintroduction also resulted in down-modulation of PLK1. With RNA interference, reduced PLK1 levels in rhabdoid cells resulted in reduced cell numbers, increased cell size, and altered morphology. The researchers concluded that drugs that induce interferon or target PLK1 or cyclin D1 may be effective. There have been at least two phase I studies of PLK1 inhibitors (BI 2536 and BI 6727) in adults with solid tumors to date, and they both seem to be well tolerated with some element of hematologic toxicity in 15–30% of patients and at least stable disease in up to 40% of patients (Frost et al., 2012; Schoffski et al., 2012).

**CYCLIN D1**

Further investigation into the association of INI1 and cyclin D1 showed that loss of INI1 results in derepression of the transcription of cyclin D1, which may drive the cell through G1 cell cycle restriction. A group at Albert Einstein College of Medicine generated \( \text{Ini}^{+/−} \) mice and showed that they have an increased incidence of rhabdoid tumors and there is a derepression of cyclin D1. They then crossed \( \text{Ini}^{+/−} \) mice with \( \text{cyclin D1}^{−/−} \) mice and found that without cyclin D1 expression, rhabdoid tumors failed to develop. When they reintroduced INI1 into \( \text{Ini}^{−/−} \) MON cell lines, they showed repression of cyclin D1 and activation of p16\(^{INK4a}\) (Tsikitis et al., 2005). A group at CHOP investigated 25 ATRT and 11 non-CNS MRT samples with confirmed SMARCB1 loss. They aimed to correlate cell line and animal data with primary tumor samples, because there had been previous contradictions regarding the relationship between SMARCB1, p16\(^{INK4a}\), and cyclin D1. When staining for p16\(^{INK4a}\), they found that 17 of 25 (68%) of ATRT and four of 11 (36%) of non-CNS MRT were negative. They noted expression of cyclin D1 in 20 of 25 (80%) of ATRT and 6 of 11 (54%) of non-CNS MRT (Venneti et al., 2011). These studies showed that cyclin D1 may drive rhabdoid tumors and is expressed in a majority of primary ATRT tumor samples and may be an effective therapeutic target.

Research unrelated to ATRT has shown that HDAC inhibitors such as MS-275 or trichostatin A decrease the expression of cyclin D1 and can decrease cell proliferation in culture (Rosato et al., 2003; Hu and Colburn, 2005; Alao et al., 2006). Researchers at the University of Colorado at Denver used two ATRT cell lines and one primary short-term culture of a tumor sample to investigate the effects of three HDAC inhibitors: trichostatin A, suberoylanilide hydroxamic acid (SAHA), and SNDX-275 (Knipstein et al., 2012). They showed that all tested HDAC inhibitors decreased proliferation and that SNDX-275 increased the sensitivity of BT12 and BT16 cell lines to ionizing radiation. Retinoids such as all-trans retinoic acid have also been shown in the laboratory to inhibit cyclins and cyclin–dependent kinases, although the specific target of inhibition differs with the agent used (Kosaka et al., 2001). Other vitamin A analogs such as the retinoid bexarotene have been shown to decrease the expression of cyclin D1, and this effect can be reversed by the HDAC inhibitor trichostatin A (Li et al., 2011). The induction of the transcriptional repressor DEC2 by bexarotene thus requires histone deacetylation as a method to suppress transcription of cyclin D1. Understanding these mechanisms of action further and the application of these methods to ATRT cells for further investigation may be warranted. Based on current information, the combination of a retinoid with an HDAC inhibitor should be avoided.

**AURORA A**

The same group previously discussed from Albert Einstein College of Medicine also investigated the role of Aurora A in rhabdoid tumors (Lee et al., 2011). They used rhabdoid tumor cell lines MON, STA-WT1, and G401 and first showed that introduction of INI1 resulted in down-modulation of Aurora A by repression of gene promoter activity. When using si-Aurora A to down-modulate Aurora A in the cell lines, they saw a significant decrease in growth with enlarged cell morphology with 12–15% cell death in the treated cells and an increase in cleaved caspase 3 products. Using three primary human rhabdoid tumors, two primary mouse rhabdoid tumors, and a mouse xenograft derived from the human G401 cell line, they showed that all had a several-fold increase in Aurora A mRNA and all stained with α-Aurora A antibody. Later published data from the Pediatric Preclinical Testing Program (PPTP) showed intermediate to high response rates in rhabdoid mouse xenograft models treated with the Aurora A inhibitor MLN8237, with the most significant response seen in the KT12 cell line (Maris et al., 2010). MLN8237 is currently
in use in clinical trials for adult and pediatric patients with vari-
ed tumors, including leukemia/lymphoma, melanoma, and solid
tumors. There are many other aurora kinase inhibitors in various
stages of clinical trials and with different specificities to Aurora A,
B, or C that may be candidates for clinical trials in patients with
ATRT (Dar et al., 2010).

INSULIN-LIKE GROWTH FACTOR
Positive immunohistochemical staining with IGF-IR and its lig-
and IGF-II has been shown in two ATRT samples and suggests
that an autocrine/paracrine loop is involved in ATRT (Ogino et al.,
2001). Researchers from CHOP wanted to further investigate this
pathway and first confirmed IGF-IR expression in eight formalin-
fixed paraffin-embedded ATRT samples (D’Cunja et al., 2007).
Through Western blotting, they showed IGF-IR was more highly
expressed in ATRT than in normal brain, medulloblastoma, or
or glial tumors. BT12 and BT16 cells treated with IGF-IR antisense
oligonucleotides decreased proliferation, increased apoptosis, and
increased chemotherapeutic sensitivity to doxorubicin and cis-
platin. Due to the interest in the IGF-1 receptor signaling pathway,
a single case of ATRT was evaluated in Poland for downstream effec-
tors Akt or Erk as they relate to mTOR activation (Iozwiak et al.,
2010). They found that Akt was upregulated while an inhibitor of
Akt, PTEN, was not elevated compared with levels found in control
ATRT (Dar et al., 2010).

TYROSINE KINASES
Multiple tyrosine kinase inhibitors are available, and they are often
used for non-specific targeting of proliferative pathways in oncol-
ogy. A group in Germany investigated 5 ATRT and 18 non-CNS
MRT samples as well as two cell lines for expression of tyrosine
kinases that are inhibited by imatinib (Koos et al., 2010). Previ-
ously, there was a report that the BT12 cell line had decreased
proliferation after treatment with imatinib, although BT16 was
not affected (Narendran et al., 2008). The German group found
c-Ab1 staining in all 23 primary tumor samples as well as A204
and G401 cells. Imatinib as well as specific targeting of c-Ab1 with
siRNA significantly reduced proliferation of both cell lines. The
researchers commented on two ATRT patients treated with ima-
tinib due to tumor expression of platelet-derived growth factor
(PDGF) who did not achieve a response, and they hypothesized
that this, as well as previous failure of response in the BT16 cell
line, may both be related to c-Ab1 expression.

Three cell lines (BT12, BT16, and KCCF1) had dose-dependent
inhibition of growth when exposed to sorafenib and sunitinib
(Jayanthan et al., 2011). Analysis of the supernatant of cell
culture media contained significant levels of PDGF and vascular
endothelial growth factor. After showing that all three cell lines
were affected by the tyrosine kinase inhibitors as well as irinote-
can alone, the group showed that there are synergistic effects on
cytotoxicity when used in combination. Others have reported that
expression of epidermal growth factor receptor was absent in nine
tumor samples of ATRT tested by FISH and immunohistochem-
istry (Jeibmann et al., 2006) and suggested that this may not be an
effective target in ATRT.

It is difficult to take early preclinical work and translate it
quickly to the clinical realm but this is desperately needed in a
tumor such as ATRT with such dismal outcomes. Newer methods
of high throughput screening and “clinics” of experimental ani-
mal have sped the identification of new effective drugs but again
may not translate into clinical effectiveness. As it is always a con-
cern with preclinical data the use of cultured cell lines may not accu-
ately represent the biology of the primary disease but is a cost
effective means to new target identification. As discussed above,
PLK1 levels have only been investigated in a single cell line and
thus this target has the weakest evidence for proceeding further
with clinical applications. Further work is needed with primary
tumor samples, primary cell culture, and animal models. Aurora
kinase A has the most compelling preclinical data as investiga-
tions have included cell line, primary tumor, and mouse xenograft
models and some investigators have proceeded with clinical trials
using MLN8237 for ATRT. Cyclin D1 is the target with the sec-
ond most interesting preclinical data with cell line work in only a
single cell line but further investigations included a mouse model
showing that cyclin D1 seems necessary for tumor formation.
This was further validated by CHOP with 80% cyclin D1 expression
of 25 ATRT primary tumor samples. HDAC inhibitors and retinoids
have been in use in pediatric oncology for many years and may be
quickly applied to ATRT although more specific inhibitors of
cyclin D1 would give better therapeutic information. See Figure 1
for a summary of the current targets identified in this review.

CONCLUSION
ATRT is an aggressive malignancy with poor survival especially in
patients with metastatic disease and in those who are younger
than 3 years old at diagnosis. Multiple therapeutic approaches
have been attempted over the last two decades in an attempt to
increase survival in these patients without much success. RT seems
to be the most important component of therapy but is often not
an option. Survival seems to be better with focal radiation, and
there may be a role for intrathecal chemotherapy in patients who
are not candidates for radiation. There is no accepted standard
chemotherapy, but intensive alkylator-based chemotherapy regi-
mens, regimens with high-dose methotrexate, and regimens that
include HDC with stem cell rescue may be more effective in these
patients. Efforts to delay radiation often fail, and most reported
cases of survivors, even when including HDC with stem cell rescue,
frequently require repeat surgery and radiation.

More potential therapeutic targets have become apparent
as we learn more about the biological mechanisms that drive
tumor formation and proliferation. Cell line data and preclinical
mouse models are not ideal but are necessary to determine the
effectiveness of chemotherapy and small molecule inhibitors. It is unlikely that any of these agents alone will result in increased survival, and they must be combined with current intensive therapy if they are expected to have any lasting effects. Combinations of these targeted agents will also likely be required, just as our current therapy includes chemotherapy with different targets to affect cell cycle progression.

More rapid progression of these agents from the laboratory to the clinic is needed. Many agents described in this review are already in clinical use but have not had reported use in ATRT, and these agents may be able to move forward more quickly into clinical trials. Current therapy seems to be reaching the maximum levels of tolerable intensification without bringing a significant change in outcomes, and new approaches are desperately needed to advance therapy.

ACKNOWLEDGMENTS
The authors would like to acknowledge the assistance of David Galloway with St. Jude Department of Scientific Editing. This work was supported by the Noyes Brain Tumor Foundation, Musicians Against Childhood Cancer (MACC), and American Lebanese Syrian Associated Charities (ALASC).

REFERENCES
Adam, P. J., Ostermann, E., Lamche, H. R., Hofmann, M. H., Kroez, M., Borges, E., and Adolf, G. R. (2011). Pharmacodynamic properties and antitumor efficacy of BI 836845, a fully human IGF ligand neutralizing antibody. Mol. Cancer Ther. 10(Suppl. 11), abstr. A208.
Agranovich, A. L., Ang, L. C., Griebel, K. T., Boller, D., Adam, P. J., Ostermann, E., Lamche, E. W., Coombes, R. C., and Manley, P. E. (2009). Childhood atypical teratoid rhabdoid tumor of the central nervous system: a meta-analysis of observational studies. J. Pediatr. Hematol. Oncol. 31, 651–663.
Beckwith, J. B. and Palmer, N. F. (1978). Histopathology and prognosis of Wilms tumors: results from the First National Wilms' Tumor Study. Cancer 41, 1937–1948.
Biegel, J. A. (2006). Molecular genetics of atypical teratoid/rhabdoid tumor. Neurosurg. Focus 20, E11.
Biegel, J. A., Tan, L., Zhang, E., Winwright, L., Russo, P., and Ronke, L. B. (2002). Alterations of the H3K9M5/INII gene in central nervous system atypical teratoid/rhabdoid tumors and renal and extrarenal rhabdoid tumors. Clin. Cancer Res. 8, 3461–3467.
Biernat, W. (2000). 2000 World Health Organization classification of tumors of the nervous system. Pol. J. Pathol. 51, 107–114.
Biggs, P. J., Garen, P. D., Powers, J. M., and Garvin, A. J. (1987). Malignant rhabdoid tumor of the central nervous system. Hum. Pathol. 18, 332–337.
Bikowska, B., Grajkowska, W., and Jozwiak, J. (2011). Atypical teratoid/rhabdoid tumor: short clinical description and insight into possible mechanism of the disease. Eur. J. Neurol. 18, 813–818.
Bonnin, J. M., Rubenstein, L. J., Palmer, N. F., and Beckwith, J. B. (1984). The association of embryonal tumors originating in the kidney and in the brain. A report of seven cases. Cancer 54, 2137–2146.
Buscarinollo, D. L., Park, H. S., Roberts, K. B., and Yu, J. B. (2011). Survival outcomes in atypical teratoid rhabdoid tumor for patients undergoing radiotherapy in a Surveillance, Epidemiology, and End Results analysis. Cancer 217, 831–841.
Chen, Y. W., Wong, T. T., Ho, D. M., Huang, P. I., Chang, K. P., Shiu, C. Y., and Yen, S. H. (2006). Impact of radiotherapy for pediatric CNS atypical teratoid/rhabdoid tumor (single institute experience). Int. J. Radiat. Oncol. Biol. Phys. 64, 1038–1043.
Choi, S. N., Limmerman, M. A., Yao, X., Cohen, K. J., Burger, P., Biegel, J. A., Ronke-Adams, L. B., Fisher, M. J., Janas, A., Mazewski, C., Goldman, S., Manley, P. E., Bowers, D. C., Kendell, A., Rubin, J., Turner, C. D., Marcus, K. J., Gounnevrova, L., Ulrich, N. J., and Kieran, M. W. (2009). Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. J. Clin. Oncol. 27, 385–389.
Chou, S. M., and Anderson, J. S. (1991). Primary CNS malignant rhabdoid tumor (MRT): report of two cases and review of literature. Clin. Neuropathol. 10, 1–10.
Dar, A. A., Goff, L. W., Majid, S., Berlin, J., and El-Rifai, W. (2010). Aurora kinase inhibitors – rising stars in cancer therapeutic? Mol. Cancer Ther. 9, 268–278.

Ginn and Gajjar ATRT therapy and directions

FIGURE 1 | Potential therapeutic targets in ATRT. Studying the effects of the reintroduction of INI1 as well as the effects of its loss has led to the identification of multiple potential therapeutic targets. INI1 loss leads to increased cyclin D1 which propagates the cell through the G1-S checkpoint. HDAC inhibitors as well as Vitamin A analogs such as retinoids and rexinoids have been shown to inhibit cyclin D1. Aurora A signaling has also been shown to be important in ATRT and multiple inhibitors of Aurora kinase signaling are available. IGF-IR signaling may also play a role in ATRT and inhibitors are available for testing.
D’Cunha, J., Shalaby, T., Rivera, P., Von Buren, A., Patti, R., Heppner, F. L., Arcaro, A., Rorke-Adams, L. B., Phillips, P. C., and Grootz, M. A. (2007). Antisense treatment of IGF-IR induces apoptosis and enhances chemosensitivity in central nervous system atypical teratoid/rhabdoid tumours cells. *Eur. J. Cancer* 43, 1581–1589.

Fidani, P., De Ioris, M. A., Serra, A., De Sio, L., Iari, L., Cozza, R., Boldrini, R., Milano, G. M., Garre, M. L., and Donfrancesco, A. (2009). A multimodal strategy based on surgery, radiotherapy, ICE regimen and high dose chemotherapy in atypical teratoid/rhabdoid tumours: a single institution experience. *J. Neurooncol.* 92, 177–183.

Finkelstein-Schuchter, T., Gassas, A., Mabbott, D., Huang, A., Bartels, U., Tabori, U., Janzen, L., Hawkins, C., Taylor, M., and Bouffet, E. (2010). Atypical teratoid or rhabdoid tumors: improved outcome with high-dose chemotherapy. *J. Pediatr. Hematol. Oncol.* 32, e182–e186.

Friedlander, T. W., Weinberg, V. K., Frontiers in Oncology | Pediatric Oncology | Ginn and Gajjar ATRT therapy and directions

Gardner, S. L., Asgharzadeh, S., Green, with non-metastatic hormone receptor inhibition with nordihydroguaiaretic acid in growth factor receptor inhibition. *Curr. Oncol.* 17, 4721–4730.

Getz, G., and Roberts, C. W. (2012). Inhibition of the Akt/mTOR pathway in a patient with atypical teratoid/rhabdoid tumor. *N Engl. J. Med.* 367, 95–104.

Ginocchio, A., Zakowski, A., Cimica, V., Zagzag, D., and Kalpana, G. V. (2011). Aurora A is a repressor of the chromatin remodeler INI1 that regulates cyclin D1 transcription by inducing nuclear factor-kappaB/p65 DNA binding. *Acta Neuropathol.* 99, 482–488.

Ho, P. S., Lee, W. H., Chen, C. Y., Chou, T. Y., Wang, Y. C., Sun, M. J., and Liao, W. Y. (1990). Primary malignant rhabdoid tumor of the brain: CT characteristics. *J. Comput. Assist. Tomogr.* 14, 461–463.

Hu, J., and Colburn, N. H. (2005). The rexinoid bexarotene represses protein INI1/hSNF5 required for rhabdoid tumor cell survival. *Cancer Cell* 29, 2983–2988.

Lee, C., Cimica, V., Ramachandra, N., Zagzag, D., and Kalpana, G. V. (2007). Activation of Akt/mTOR pathway in a patient with atypical teratoid/rhabdoid tumor. *Folia Neuropathol.* 45, 155–163.

Leibman, A., Buerger, H., Fruhwald, M., and Hasselblatt, G. (2012). Phase I study of the inhibitor MLN8237 by the Pediatric Preclinical Testing Program for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review. *Acta Neuropathol. Com.*, 166–177.
Rorke, L. B., Packer, R. J., and Biegel, J. A. (1996). Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood: definition of an entity. J. Neurosurg. 85, 56–65.

Rosato, R. R., Almenara, J. A., and Grant, S. (2003). The histone deacteyls inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1. Cancer Res. 63, 3637–3645.

Rowe, D. L., Ozdy, T., Bender, L. M., and Nahta, R. (2008). Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer. Mol. Cancer Ther. 1900–1908.

Sato, H., Goishi, J., Sogabe, T., Uozumi, T., Kiyi, K., and Migita, K. (1993). Primary malignant rhabdoid tumor of the central nervous system: case report and review of the literature. Surg. Neurol. 40, 429–434.

Schofski, P., Awada, A., Dumer, H., Gil, T., Bartholomeus, S., Wolter, P., Taton, M., Frisch, H., Glomb, P., and Munzert, G. (2012). A phase I/dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. Eur. J. Cancer 48, 179–186.

Shih, C. S., Hale, G. A., Gronewold, L., Tong, X., Lamington, F. H., Gilger, E. A., Srivastava, D. K., Kun, L. E., Gajjar, A., and Fouladi, M. (2008). High-dose chemotherapy with autologous stem cell rescue for children with recurrent malignant brain tumors. Cancer 112, 1345–1355.

Tkacztz, T. M., Fuller, C. E., Blaney, S., Fouladi, M., Broniscer, A., Merchant, T. E., Krasin, M., Dalton, J., Hale, G., Kun, L. E., Wallace, D., Gilbertson, R. J., and Gajjar, A. (2005). Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy. J. Clin. Oncol. 23, 1491–1499.

Tsikitis, M., Zhang, Z., Edelman, W., Zaggag, D., and Kalpana, G. V. (2005). Genetic ablation of Cyclin D1 abrogates genesis of rhabdoid tumors resulting from Ini1 loss. Proc. Natl. Acad. Sci. U.S.A. 102, 12129–12134.

Venneti, S., Le, P., Martinez, D., Eaton, K. W., Syham, N., Jordan-Sciutto, K. L., Pawel, B., Biegel, J. A., and Judkins, A. R. (2011). p16INK4A and p14ARF tumor suppressor pathways are deregulated in malignant rhabdoid tumors. J. Neuropathol. Exp. Neurol. 70, 596–609.

Versteeg, I., Medjane, S., Rouillard, D., and Delattre, O. (2002). A key role of the hSNF5/INI1 tumour suppressor in the control of the G1-S transition of the cell cycle. Oncogene 21, 6403–6412.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 30 May 2012; accepted: 22 August 2012; published online: 12 September 2012.

This article was submitted to Frontiers in Pediatric Oncology, a specialty of Frontiers in Oncology.

Copyright © 2012 Ginn and Gajjar. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.